These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17208475)

  • 21. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of antigen-presenting cells in the regulation of delayed-type hypersensitivity. I. Spleen dendritic cells.
    Morikawa Y; Furotani M; Kuribayashi K; Matsuura N; Kakudo K
    Immunology; 1992 Sep; 77(1):81-7. PubMed ID: 1398768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Advances in cellular immunotherapy for malignant melanoma].
    López M; Escobar A; Alfaro J; Fodor M; Larrondo M; Ferrada C; Salazar-Onfray F
    Rev Med Chil; 2004 Sep; 132(9):1115-26. PubMed ID: 15543770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
    Nestle FO; Alijagic S; Gilliet M; Sun Y; Grabbe S; Dummer R; Burg G; Schadendorf D
    Nat Med; 1998 Mar; 4(3):328-32. PubMed ID: 9500607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
    Lesterhuis WJ; Schreibelt G; Scharenborg NM; Brouwer HM; Gerritsen MJ; Croockewit S; Coulie PG; Torensma R; Adema GJ; Figdor CG; de Vries IJ; Punt CJ
    Cancer Immunol Immunother; 2011 Feb; 60(2):249-60. PubMed ID: 21069321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.
    Trefzer U; Herberth G; Wohlan K; Milling A; Thiemann M; Sharav T; Sparbier K; Sterry W; Walden P
    Vaccine; 2005 Mar; 23(17-18):2367-73. PubMed ID: 15755630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen.
    Gyorffy S; Rodriguez-Lecompte JC; Woods JP; Foley R; Kruth S; Liaw PC; Gauldie J
    J Vet Intern Med; 2005; 19(1):56-63. PubMed ID: 15715049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.
    Matsumoto A; Haraguchi K; Takahashi T; Azuma T; Kanda Y; Tomita K; Kurokawa M; Ogawa S; Takahashi K; Chiba S; Kitamura T
    Int J Urol; 2007 Apr; 14(4):277-83. PubMed ID: 17470153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
    Tan XH; Liu C; Wan YH
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell vaccination and immunostimulation in advanced melanoma.
    Ridolfi R; Ridolfi L; Petrini M; Fiammenghi L; Riccobon A
    Expert Rev Vaccines; 2003 Dec; 2(6):825-33. PubMed ID: 14711365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma.
    Rodeberg DA; Erskine C; Celis E
    J Pediatr Surg; 2007 Aug; 42(8):1396-402. PubMed ID: 17706503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
    Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
    Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
    Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
    Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer.
    Salazar-Onfray F; Pereda C; Reyes D; López MN
    Biol Res; 2013; 46(4):431-40. PubMed ID: 24510145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
    Connerotte T; Van Pel A; Godelaine D; Tartour E; Schuler-Thurner B; Lucas S; Thielemans K; Schuler G; Coulie PG
    Cancer Res; 2008 May; 68(10):3931-40. PubMed ID: 18483279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of dendritic cell-based vaccination against infection.
    Fajardo-Moser M; Berzel S; Moll H
    Int J Med Microbiol; 2008 Jan; 298(1-2):11-20. PubMed ID: 17719274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Unveiling antigens in a non-immunogenic spontaneous murine tumor using a dendritic cell based vaccine].
    Reffo VL; Chiarella P; Bruzzo J; Bustuoabad OD; Ruggiero RA
    Medicina (B Aires); 2008; 68(4):301-4. PubMed ID: 18786887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.